Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Progyny Inc (NASDAQ: PGNY) was $20.59 for the day, up 0.19% from the previous closing price of $20.55. In other words, the price has increased by $0.19 from its previous closing price. On the day, 1.06 million shares were traded. PGNY stock price reached its highest trading level at $21.01 during the session, while it also had its lowest trading level at $20.47.
Ratios:
Our analysis of PGNY’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.80 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.31. For the most recent quarter (mrq), Quick Ratio is recorded 2.70 and its Current Ratio is at 2.70. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On December 02, 2024, JP Morgan Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $17.
Truist Downgraded its Buy to Hold on November 13, 2024, whereas the target price for the stock was revised from $26 to $19.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 04 ’25 when Swartz Allison sold 599 shares for $23.53 per share. The transaction valued at 14,094 led to the insider holds 77,407 shares of the business.
Swartz Allison bought 599 shares of PGNY for $14,094 on Sep 04 ’25. On Aug 28 ’25, another insider, Swartz Allison, who serves as the EVP, GC of the company, sold 2,398 shares for $22.96 each. As a result, the insider received 55,058 and left with 79,697 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PGNY now has a Market Capitalization of 1770377856 and an Enterprise Value of 1493914752. As of this moment, Progyny’s Price-to-Earnings (P/E) ratio for their current fiscal year is 34.96, and their Forward P/E ratio for the next fiscal year is 22.90. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.35. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.43 while its Price-to-Book (P/B) ratio in mrq is 3.44. Its current Enterprise Value per Revenue stands at 1.203 whereas that against EBITDA is 18.491.
Stock Price History:
The Beta on a monthly basis for PGNY is 1.31, which has changed by 0.2796768 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, PGNY has reached a high of $26.76, while it has fallen to a 52-week low of $13.39. The 50-Day Moving Average of the stock is -8.79%, while the 200-Day Moving Average is calculated to be -5.04%.
Shares Statistics:
PGNY traded an average of 1.10M shares per day over the past three months and 1074540 shares per day over the past ten days. A total of 85.93M shares are outstanding, with a floating share count of 71.78M. Insiders hold about 16.51% of the company’s shares, while institutions hold 96.08% stake in the company. Shares short for PGNY as of 1757894400 were 6871413 with a Short Ratio of 6.27, compared to 1755216000 on 7661466. Therefore, it implies a Short% of Shares Outstanding of 6871413 and a Short% of Float of 11.06.
Earnings Estimates
As of right now, 7.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.39, with high estimates of $0.4 and low estimates of $0.37.
Analysts are recommending an EPS of between $1.78 and $1.72 for the fiscal current year, implying an average EPS of $1.74. EPS for the following year is $1.89, with 7.0 analysts recommending between $2.05 and $1.76.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 10 analysts. It ranges from a high estimate of $304.2M to a low estimate of $292.71M. As of. The current estimate, Progyny Inc’s year-ago sales were $286.62MFor the next quarter, 10 analysts are estimating revenue of $302.6M. There is a high estimate of $312.66M for the next quarter, whereas the lowest estimate is $286.42M.
A total of 10 analysts have provided revenue estimates for PGNY’s current fiscal year. The highest revenue estimate was $1.27B, while the lowest revenue estimate was $1.24B, resulting in an average revenue estimate of $1.26B. In the same quarter a year ago, actual revenue was $1.17BBased on 10 analysts’ estimates, the company’s revenue will be $1.38B in the next fiscal year. The high estimate is $1.48B and the low estimate is $1.35B.
